Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
Rhea-AI Summary
DBVT (NYSE Euronext Paris) disclosed its total shares and voting rights as of January 31, 2026 under Article 223-16 of the AMF General Regulations.
The company reported 274,852,082 total shares and a gross total of 274,852,082 voting rights, with a net total of 274,792,237 voting rights (excluding shares without voting rights).
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
DBVT was up 4.04% while close peers CADL, OMER, ANNX, CAPR and NGNE were down between -4.60% and -6.04%, indicating stock-specific dynamics rather than a sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Warrant exercise proceeds | Positive | +0.5% | €166.7M gross proceeds from full exercise of ABSA and BS warrants. |
| Jan 12 | Voting rights update | Neutral | -5.0% | Updated total shares and voting rights as of Dec 31, 2025. |
| Jan 07 | Liquidity contract report | Neutral | +8.2% | Half-year report on liquidity contract share and cash positions. |
| Jan 05 | Voting rights update | Neutral | -10.8% | Initial disclosure of Dec 31, 2025 share and voting-right totals. |
| Dec 16 | Phase 3 trial results | Positive | -1.7% | Positive Phase 3 VITESSE topline data for VIASKIN Peanut in children 4–7. |
Operational and clinical news have often seen mixed or negative next-day reactions, while routine voting-rights disclosures have sometimes coincided with notable declines.
Over the last few months, DBV Technologies has reported several capital markets and operational milestones. On Dec 16, 2025, positive Phase 3 VITESSE topline data for VIASKIN Peanut were released, followed by an 8-K. Subsequent disclosures covered share and voting-right updates on Dec 31, 2025 and Jan 12, 2026, and a liquidity contract report on Jan 7, 2026. On Jan 16, 2026, the company announced €166.7M in gross proceeds from warrant exercises. Today’s voting-rights update continues this sequence of capital structure transparency.
Market Pulse Summary
This announcement formalizes DBV Technologies’ share capital as of January 31, 2026, reporting 274,852,082 total shares, with 274,852,082 gross and 274,792,237 net voting rights under Article 223-16 of the AMF rules. It follows prior disclosures on warrant exercises and share issuances, giving an updated reference point for ownership percentages and regulatory filings. Investors tracking historical ownership changes and governance metrics may monitor how future filings reference these new totals.
Key Terms
voting rights regulatory
isin regulatory
autorité des marchés financiers regulatory
article 223-16 regulatory
AI-generated analysis. Not financial advice.
Information Regarding the Total Number of Voting Rights and
Total Number of Shares of the Company as of January 31, 2026
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 01/31/2026 | 274,852,082 | Total gross of voting rights: 274,852,082 |
| Total net* of voting rights: 274,792,237 |
* Net total = total number of voting rights attached to shares – shares without voting rights
Attachment